News and Updates

Khartis Therapeutics launches with $95M to develop an oral pill for Thyroid Eye Disease, aiming to challenge existing biologic infusions with new tech.

Karyopharm reports Q2 2026 financial results, highlighting major strides toward an sNDA submission for a novel myelofibrosis treatment. Learn more.

Sagimet Biosciences confirms its Phase 3 trial for denifanstat is on track for 2026, marking a major step forward in treating MASH and metabolic disease.

Sumitomo Pharma has officially dosed the first patient in a Phase I/IIa trial for DSP-3077. Learn about the study's scope, safety goals, and clinical aims.

The FDA has released new guidance to broaden clinical trial eligibility for cancer patients, aiming to increase diversity and speed up drug development.

Kupando has commenced its first-in-human Phase 1 clinical trial. Discover the latest updates on this investigational therapy’s safety and development path.

Are high ROI claims in clinical trials ignoring site-level costs? Discover why sustainable infrastructure is essential for the future of drug development.

Nafamostat receives key KDIGO endorsement for CRRT as Talphera nears completion of the NEPHRO trial. Discover how this shift impacts ICU patient care.

ArkBio has launched clinical trials for its new influenza drug, AK0406. Learn how this antiviral candidate could impact future respiratory infection care.

Atea Pharmaceuticals' bemnifosbuvir and ruzasvir combo succeeds in Phase 3 HCV trials, showing high SVR12 rates and strong potential for future approval.